FOI 5837 Patients with juvenile ideopathic arthritis treated with certain drugs

Date: 04 December 2019 to 04 December 2022

I would like to understand how patients with juvenile ideopathic arthritis are being treated. So, in the last 6 months, how many patient(s) with juvenile ideopathic arthritis have been treated with:

Humira (adalimumab)

Amgevita (adalimumab)

Imraldi (adalimumab)

Hyrimoz (adalimumab)

Hulio (adalimumab)

Tocilizumab

Abatacept

Enbrel (etanercept)

Erelzi (etanercept)

Benepali (etanercept)

Golimumab

Remicade (infliximab)

Remsima (infliximab)

Inflectra (infliximab)

Flixabi (infliximab)

Canakinumab

Anakinra

  • Request ID:
    FOI 5837
  • Category:
    Clinical - Drugs
  • Response:

    I would like to understand how patients with juvenile ideopathic arthritis are being treated. So, in the last 6 months, how many patient(s) with juvenile ideopathic arthritis have been treated with:

    Humira (adalimumab)

    Amgevita (adalimumab)

    Imraldi (adalimumab)

    Hyrimoz (adalimumab)

    Hulio (adalimumab)

    Tocilizumab

    Abatacept

    Enbrel (etanercept)

    Erelzi (etanercept)

    Benepali (etanercept)

    Golimumab

    Remicade (infliximab)

    Remsima (infliximab)

    Inflectra (infliximab)

    Flixabi (infliximab)

    Canakinumab

    Anakinra

    ** Medway NHS Foundation Trust regret that we are unable to answer your question as this data is not collated.    

    However, we can confirm that there were 9 patients admitted with “juvenile ideopathic arthritis” between 01/05/2019 to 31/10/2019.

    The Trust’s Pharmacy department can also confirm the number of patients prescribed the above treatments, however, they are unable to confirm the indication for the treatment as this is not recorded.  Please see attached for information.